← Back to guidelines
Palliative Care6 papers

Severe bronchopulmonary dysplasia of newborn

Last edited:

Overview

Severe bronchopulmonary dysplasia (BPD) is a significant respiratory complication affecting extremely preterm infants, typically those born before 29 weeks of gestational age. This condition arises from prolonged mechanical ventilation and oxygen therapy, leading to chronic lung injury characterized by abnormal lung development, inflammation, and fibrosis. The prevalence of severe BPD is notably high, with studies indicating that approximately 32.6% of extremely preterm infants develop this condition, underscoring its clinical importance and the need for meticulous management strategies [PMID:34428130]. Recent trends in neonatal care have seen a shift towards less invasive respiratory support modalities, such as high-flow nasal cannula (HFNC) and continuous positive airway pressure (CPAP), aiming to mitigate the risk of BPD while maintaining adequate respiratory support [PMID:37442954]. However, the efficacy and potential long-term impacts of these interventions remain areas of active investigation.

Pathophysiology

The development of severe BPD is intricately linked to early-life respiratory stressors, particularly hypoxemia. A post hoc analysis of extremely preterm infants highlighted that frequent and prolonged episodes of hypoxemia (oxygen saturations <80% for ≥1 minute) within the first week of life are strongly associated with the subsequent development of severe BPD [PMID:34428130]. These hypoxic events trigger a cascade of inflammatory responses and oxidative stress, leading to alveolar simplification and impaired lung development. The initial vulnerability of the preterm lung, combined with mechanical ventilation and high oxygen exposure, exacerbates these processes, fostering a microenvironment conducive to chronic inflammation and fibrosis. Understanding these early risk factors underscores the importance of vigilant monitoring and proactive interventions to minimize hypoxemic episodes in the neonatal period.

Epidemiology

The epidemiology of severe BPD reflects evolving trends in neonatal care practices. Over the past five years (2016-2020), there has been a notable shift away from invasive mechanical ventilation (MV) towards less invasive respiratory support methods, such as high-flow nasal cannula (HFNC) and CPAP, in neonatal intensive care units (NICUs) [PMID:37442954]. This transition aims to reduce lung injury and improve outcomes for preterm infants. Despite these advancements, the prevalence of severe BPD remains substantial, with studies reporting that nearly one-third (32.6%) of extremely preterm infants (born <29 weeks of gestational age) develop this condition [PMID:34428130]. This high incidence highlights the persistent challenge in preventing chronic lung disease despite improvements in supportive care techniques. The ongoing surveillance of these trends is crucial for refining clinical practices and improving long-term respiratory outcomes.

Clinical Presentation

Infants at risk for severe BPD often present with complex respiratory needs shortly after birth. Among infants born before 29 weeks of gestational age, prolonged reliance on various respiratory support modalities, including MV, CPAP, HFNC, and low-flow oxygen therapy, is strongly correlated with an increased risk of developing BPD [PMID:37442954]. Early clinical signs may include persistent tachypnea, retractions, and increased oxygen requirements. Significant differences in hypoxemia rates between infants who develop severe BPD and those who do not become apparent as early as the first week of life, indicating that early monitoring of oxygen saturation could serve as a predictive tool for identifying high-risk infants [PMID:34428130]. These early indicators emphasize the importance of meticulous respiratory monitoring and timely intervention to mitigate the progression towards severe BPD.

Diagnosis

Diagnosing severe BPD involves a comprehensive assessment of respiratory support requirements and clinical outcomes over time. Clinicians track the duration and type of respiratory support modalities used, such as MV, CPAP, HFNC, and oxygen therapy, as key diagnostic indicators [PMID:37442954]. Persistent need for oxygen beyond 36 weeks postmenstrual age, failure to wean from ventilatory support, and radiographic evidence of characteristic lung changes (such as hyperinflation, air trapping, and cystic changes) are critical components of the diagnostic criteria. Additionally, clinical parameters like growth retardation, feeding difficulties, and recurrent respiratory infections further support the diagnosis. Early and accurate diagnosis is pivotal for initiating appropriate management strategies to improve outcomes.

Management

The management of severe BPD integrates multiple therapeutic approaches aimed at reducing lung injury and supporting respiratory function. Despite the growing adoption of non-invasive modalities like HFNC, there remains a critical knowledge gap regarding their long-term impact on BPD incidence [PMID:37442954]. Interventions focused on minimizing hypoxemia exposure are particularly crucial, given the strong association between prolonged hypoxemia and BPD development [PMID:34428130]. Key management strategies include:

  • Respiratory Support Modalities: Transitioning from invasive MV to less injurious methods like CPAP and HFNC can help reduce lung injury. However, the optimal timing and criteria for these transitions require further investigation [PMID:27351566].
  • Surfactant Therapy: Use of surfactant therapy, guided by criteria such as FiO2 ≥0.4 and MAP ≥10 cm H2O, is widely supported by clinicians for managing respiratory distress syndrome (RDS) [PMID:27351566].
  • Caffeine Therapy: Caffeine is frequently employed to prevent BPD, with a significant majority (73%) of clinicians reporting its use in their practice [PMID:27351566].
  • Steroids: The use of corticosteroids for BPD prevention or treatment is less common, reserved primarily for cases with multiple extubation failures or prolonged reliance on ventilatory support beyond 8 weeks [PMID:27351566]. Ethical considerations also come into play, particularly in managing infants with severe, life-limiting conditions, where discussions around palliative care and end-of-life options, guided by frameworks like the Groningen protocol, are essential [PMID:16507660, PMID:16140716].
  • These multifaceted approaches aim to balance respiratory support with minimizing further lung damage, tailored to the individual needs of each infant.

    Prognosis & Follow-up

    The prognosis for infants with severe BPD is multifaceted, marked by improved survival rates alongside persistent respiratory morbidity. Advances in neonatal care have significantly enhanced survival rates for extremely preterm infants, yet these survivors often face long-term respiratory challenges, including chronic lung disease [PMID:37442954]. Follow-up care is critical, encompassing regular pulmonary function assessments, monitoring for recurrent respiratory infections, and addressing developmental delays that may accompany prolonged respiratory support. Long-term surveillance helps in early detection and management of complications, ensuring optimal quality of life. Ethical considerations in end-of-life care for infants with severe, incurable conditions remain paramount, necessitating structured discussions around palliative care and the potential role of deliberate ending of life under specific circumstances, as outlined by protocols like the Groningen protocol [PMID:16507660, PMID:16140716]. These discussions aim to balance medical intervention with respect for the infant's quality of life and family values.

    Special Populations

    Infants with severe BPD, especially those with additional comorbidities or those born to mothers with complex medical histories, present unique challenges. Ethical considerations are particularly pronounced in managing these infants, where decisions about aggressive versus palliative care can be fraught with moral and ethical dilemmas. The Groningen protocol provides a structured framework for addressing these dilemmas, emphasizing the importance of multidisciplinary team involvement in decision-making processes [PMID:16507660, PMID:16140716]. Clinicians must navigate issues of autonomy, potential biases in prognostic assessments, and the nuanced evaluation of quality of life versus the infant's will to live. Tailored ethical frameworks are essential to support families and healthcare providers in making informed, compassionate decisions that respect the infant's best interests and family values.

    Key Recommendations

  • Early Monitoring and Intervention: Vigilantly monitor oxygen saturation levels in the neonatal period to identify and mitigate early hypoxemic episodes, which are strongly linked to severe BPD development [PMID:34428130].
  • Transition to Less Invasive Support: Gradually transition from invasive mechanical ventilation to less injurious modalities like CPAP and HFNC to reduce lung injury risk, while closely monitoring clinical outcomes [PMID:37442954, PMID:27351566].
  • Evidence-Based Therapies: Utilize surfactant therapy based on specific clinical criteria (FiO2 ≥0.4 and MAP ≥10 cm H2O) and consider caffeine therapy to prevent BPD, given their widespread clinical support [PMID:27351566].
  • Selective Use of Steroids: Reserve corticosteroid use for infants with multiple extubation failures or prolonged ventilatory dependence beyond 8 weeks, balancing potential benefits against risks [PMID:27351566].
  • Ethical End-of-Life Discussions: Engage in structured, multidisciplinary discussions regarding palliative care and end-of-life options for infants with severe, life-limiting conditions, guided by ethical frameworks like the Groningen protocol [PMID:16507660, PMID:16140716].
  • Comprehensive Follow-Up Care: Ensure long-term follow-up to monitor respiratory health, developmental milestones, and overall quality of life, adapting care plans as needed based on evolving clinical status [PMID:37442954].
  • These recommendations aim to provide a balanced approach to managing severe BPD, integrating clinical evidence with ethical considerations to optimize outcomes for affected infants.

    References

    1 Algarni SS, Ali K, Alsaif S, Aljuaid N, Alzahrani R, Albassam M et al.. Changes in the patterns of respiratory support and incidence of bronchopulmonary dysplasia; a single center experience. BMC pediatrics 2023. link 2 Jensen EA, Whyte RK, Schmidt B, Bassler D, Vain NE, Roberts RS. Association between Intermittent Hypoxemia and Severe Bronchopulmonary Dysplasia in Preterm Infants. American journal of respiratory and critical care medicine 2021. link 3 Jotkowitz AB, Glick S. The Groningen protocol: another perspective. Journal of medical ethics 2006. link 4 Parat S, Mhanna MJ. Respiratory management of extremely low birth weight infants: survey of neonatal specialists. World journal of pediatrics : WJP 2016. link 5 Verhagen AA, Sauer PJ. End-of-life decisions in newborns: an approach from The Netherlands. Pediatrics 2005. link

    5 papers cited of 6 indexed.

    Original source

    1. [1]
      Changes in the patterns of respiratory support and incidence of bronchopulmonary dysplasia; a single center experience.Algarni SS, Ali K, Alsaif S, Aljuaid N, Alzahrani R, Albassam M et al. BMC pediatrics (2023)
    2. [2]
      Association between Intermittent Hypoxemia and Severe Bronchopulmonary Dysplasia in Preterm Infants.Jensen EA, Whyte RK, Schmidt B, Bassler D, Vain NE, Roberts RS American journal of respiratory and critical care medicine (2021)
    3. [3]
      The Groningen protocol: another perspective.Jotkowitz AB, Glick S Journal of medical ethics (2006)
    4. [4]
      Respiratory management of extremely low birth weight infants: survey of neonatal specialists.Parat S, Mhanna MJ World journal of pediatrics : WJP (2016)
    5. [5]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG